Natural Products in Psychiatry: Evidence vs Hype

COMMENTARY

The dietary supplement industry is no cottage side-hustle; it is a global machine. Recent market estimates put the global dietary supplements market at roughly $209.52 billion in 2025 (with forecasts climbing fast).¹ That revenue exists despite the reality every psychiatrist knows: for many supplements, the evidence base is thin, the effect sizes are modest, and the quality control is inconsistent.

And yet, supplements are having a cultural moment. Wellness influencers push them. Patients ask for them. And yes, some clinicians promote them with a confidence level that would make a US Food and Drug Administration (FDA) advisory committee blush.

The common storyline goes like this: Supplements are not “Big Pharma.” They are natural. They are pure. They are the antidote to a greedy, corrupt medical-industrial complex.

Here is the psychiatry unfiltered version: both industries sell hope. Both have marketing. Both cherry-pick. Both have financial incentives. The biggest difference is not morality; it is regulation. Under the Dietary Supplement Health and Education Act of 1994, the FDA does not approve dietary supplements for safety or effectiveness before they are marketed. In many cases, companies can bring products to market without even notifying FDA.

So, whether you love supplements, hate them, or just want everyone to stop talking about “toxins” on TikTok, your patients are using these products. Often alongside prescribed medication. Sometimes instead of it. Our job is not to sneer. It is to guide: what has evidence, what is low risk, what is snake oil, and what might quietly hurt someone.

The Patient Who Wants to “Go Natural”: What Is the Move?

We all know this patient:

• medication-averse
• suspicious of institutions
• convinced there is a “natural cure” being withheld
• already taking 6 supplements they didn’t mention until you asked specifically

If we are going to help patients make informed choices, we need to address 3 questions:

1. Does it work?
2. Is it safe for them, with their meds, and at that dose?
3. Is the product what it claims to be? This is not a small issue.

Let’s talk evidence condition by condition.

Anxiety Disorders: Where Supplements Have Their Best Shot

Anxiety disorders are the most common mental health conditions in US adults, with approximately 19.1% past-year prevalence.² That prevalence makes anxiety a prime target for “natural” marketing.

Lavender oil (Silexan)

If you want one “natural” option that is supported by decent RCTs, consider Silexan. Meta-analytic evidence supports benefit across anxiety presentations, including generalized anxiety disorder and subsyndromal anxiety.³ RCT data exist comparing Silexan with placebo and comparators.^4,5

For mild-to-moderate anxiety, Silexan is one of the better-supported OTC options. Side effects are generally mild: lavender burps, GI symptoms, headache.^4,5

Dose: Typically, 80 to 160 mg daily (often sold over-the-counter as CalmAid).

Kava (Piper methysticum)

Kava has evidence for short-term anxiolysis vs placebo.⁶ The problem is not “does it work?,” but instead safety and product variability. Hepatotoxicity concerns have limited uptake and deserve real caution, especially with alcohol or hepatotoxic meds.⁶

Kava is potentially effective short-term, but not a casual recommendation in a world where product composition varies.

Dose: Up to 300 mg per day.

Ashwagandha (Withania somnifera)

Ashwagandha is the supplement equivalent of a viral trend except there is some emerging RCT/meta-analytic signal for stress/anxiety reduction.⁷ The certainty is still low-to-moderate, many studies are small, and heterogeneity is real.⁷

Claims about cortisol reductions show up in the literature, but we should be careful not to turn a biomarker shift into a clinical miracle.^7,8 Adverse effects include mild GI effects and somnolence; rare liver injury case reports exist, so avoid casual use in patients with liver disease or hepatotoxic meds.

Dose: When used in trials, it was commonly 300 to 600 mg/day standardized extract.⁷

Depression: Where “Natural” Needs Precision, Not Vibes

Given that depression is one of the most common reasons patients present for psychiatric care, it is sensible to have thoughtfully selected natural options available, whether as primary or adjunctive treatment.

Omega-3 fatty acids (EPA/DHA)

Omega-3s are not all the same, and most patients buy the wrong ratio.

Evidence suggests benefit is more consistent when:EPA is dominant (≥60%) or pure EPA, and the dose is adequate.^9-11 There is also a biologically plausible signal that omega-3s may help an inflammatory subtype (eg, higher CRP), supported by proof-of-concept work.¹²

Dose:The range common in trials and clinical practice is approximately 1 to 4 g/day total omega-3s (EPA+DHA), with EPA dominance at least a 2:1 ratio.^9-11

SAMe

Mechanism is plausible (methyl donor; monoamine synthesis pathways), but the clinical literature is mixed. Recent meta-analyses suggest possible benefit, particularly as augmentation, though study size and heterogeneity limit certainty.^12,13 Cochrane has historically concluded evidence is insufficient for firm conclusions.¹⁴

Key safety point: avoid in bipolar disorder or patients with manic vulnerability (activation/mania risk).

Dose: Start with approximately 400 mg/day; target often 800 to 1600 mg/day, titrating as tolerated.^12-14

L-methylfolate

This is one of the more defensible “nutraceutical” augmentations in depression, particularly in SSRI partial/nonresponse. Meta-analytic evidence supports augmentation effects, with 15 mg outperforming lower doses.^15,16

Who to consider: SSRI nonresponse, obesity/inflammation signals, poor nutrition, alcohol use disorder, or suspected folate pathway issues.^15,16

Dose: 15 mg/day.

Vitamin D

The evidence is most compelling when treating deficiency, not depression in patients with normal levels.¹⁷

Practical point: check 25-OH vitamin D and correct deficiency; do not promise it is an antidepressant.

Dose: 2000 IU daily or 10,000 IU weekly.

Probiotics (“Psychobiotics”)

Yes, gut-brain axis mechanisms are real. But the supplement market jumped from “interesting science” to “this yogurt fixed my depression” at warp speed.Meta-analyses suggest small-to-moderate benefit signals for depression and anxiety, limited by study size, strain heterogeneity, and short follow-up.¹⁸ Some studies suggest probiotics in combination with antidepressant treatment are effective and well tolerated for treatment resistant depression.¹⁹ Mechanistic claims (neurotransmitter modulation, inflammation, HPA axis changes) are plausible but not a license to oversell.²⁰

Product guidance (harm reduction):

• Prefer multi-strain products (Lactobacillus/Bifidobacterium strains have the best evidence base).²⁰
• CFU dosing commonly lands in the billions (2 to 10B+ CFU), though “more” is not always “better.”
• Avoid in immunocompromised patients.

There is no FDA-approved “psychobiotic” medication for depression/anxiety. This is marketing language, not regulatory reality.

Dose: No established consensus 1 capsule of 1-10 billion CFU/day.

Schizophrenia: NAC as Adjunct, Not Replacement

Schizophrenia is not the place for magical thinking. Antipsychotics remain foundational.

That said, N-acetylcysteine (NAC) has RCT meta-analytic support as an adjunct, with signals for negative symptom and some cognitive domains over longer durations.²¹

Dose: Start with approximately 1200 mg/day; target commonly 2000 mg/day, sometimes higher (up to approximately 3600 mg/day) in studies.²¹

Insomnia: Melatonin: Useful, But Not Magic

Melatonin has its best evidence for circadian rhythm sleep-wake disorders (jet lag, shift work disorder, delayed sleep-wake phase disorder) rather than broad “insomnia” as a diagnosis.²² AASM practice parameters support timed melatonin for jet lag and other circadian disorders.

For primary insomnia in adults, effects are often modest and inconsistent across reviews, dosing and timing matter.

Practical guidance:

• Lower doses often suffice (0.3 to 3 mg), and timing (often 1 to 3 hours pre-bed for circadian shifting) can matter more than dose.
• Consider controlled/extended-release in older adults when sleep maintenance is the complaint, while acknowledging the evidence is mixed.

Quality Control: The Part Everyone Ignores Until Something Goes Wrong

This is where “natural” gets dangerous.

Because supplements are not FDA pre-approved for safety/efficacy, clinicians should push patients toward products with credible third-party verification.

Examples:

• USP Verified: confirms ingredients, potency, and contaminant standards.
• NSF certification (including Certified for Sport): tests for label accuracy/contaminants; widely used in athletics.
• ConsumerLab: independent testing and quality certification program.

Tell patients the truth: many products do not contain what the label says, and “proprietary blend” is often code for “just trust me.”

Concluding Thoughts: Supplements Are Not the Enemy But Marketing Delusions Are

Natural products can have a role:

• as adjuncts
• in mild-to-moderate illness
• when patients refuse standard meds
• when there is a clear deficiency or biologically coherent target

But the real clinical mission is harm reduction with intellectual honesty:

• Don’t oversell.
• Don’t demonize.
• Don’t let ideology replace evidence.

And above all: “natural” is not a synonym for safe, effective, or pure. It is a marketing adjective.

Dr Rossi is a board-certified psychiatrist specializing in inpatient and consultation-liaison psychiatry. His work focuses on evidence-based treatment, complex mood and psychotic disorders, and practical clinical decision-making. He is passionate about education, thoughtful skepticism, and advancing psychiatry through honest, nuanced discussion.

References

1. Dietary Supplements Market Size, Share & Trends Analysis Report by Ingredients, Type, Form, Application, End User, Distribution Channel, Region, and Segment Forecasts, 2025–2033. Grand View Research; 2024. Accessed March 4, 2026. https://www.grandviewresearch.com/industry-analysis/dietary-supplements-market-report

2. Any anxiety disorder. National Institute of Mental Health. Accessed March 2, 2026. https://www.nimh.nih.gov/health/statistics/any-anxiety-disorder

3. Dold M, Bartova L, Volz HP, et al. Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci. 2023;273(7):1615-1628.

4. Kasper S, Gastpar M, Müller WE, et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder: a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol. 2014;17(6):859-869.

5. Kasper S, Volz HP, Dienel A, Schläfke S. Efficacy of Silexan in mixed anxiety-depression: a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2016;26(2):331-340.

6. Smith K, Leiras C. The effectiveness and safety of Kava Kava for treating anxiety symptoms: a systematic review and analysis of randomized clinical trials. Complement Ther Clin Pract. 2018;33:107-117.

7. Akhgarjand C, Asoudeh F, Bagheri A, et al. Does Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2022;36(11):4115-4124.

8. Bachour G, Samir A, Haddad S, et al. Effects of Ashwagandha supplements on cortisol, stress, and anxiety levels in adults: a systematic review and meta-analysis. BJPsych Open. 2025;11(S1):S39.

9. Norouziasl R, Zeraattalab-Motlagh S, Jayedi A, Shab-Bidar S. Efficacy and safety of n-3 fatty acids supplementation on depression: a systematic review and dose–response meta-analysis of randomised controlled trials. Br J Nutr. 2024;131(4):658-671.

10. Liao Y, Xie B, Zhang H, et al. Efficacy of omega-3 PUFAs in depression: a meta-analysis. Transl Psychiatry. 2019;9(1):190.

11. Norouziasl R, Zeraattalab-Motlagh S, Jayedi A, Shab-Bidar S. Efficacy and safety of n-3 fatty acids supplementation on depression: a systematic review and dose–response meta-analysis of randomised controlled trials. Br J Nutr. 2024;131(4):658-671.

12. Limveeraprajak N, Nakhawatchana S, Visukamol A, et al. Efficacy and acceptability of S-adenosyl-L-methionine (SAMe) for depressed patients: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2024;132:110985.

13. Peng TR, Cheng HY, Wu TW. S-Adenosylmethionine (SAMe) as an adjuvant therapy for patients with depression: an updated systematic review and meta-analysis. Gen Hosp Psychiatry. 2024;86:118-126.

14. Galizia I, Oldani L, Macritchie K, et al. S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database Syst Rev. 2016;(10):CD011286.

15. Maruf AA, Poweleit EA, Brown LC, et al. Systematic review and meta-analysis of L-methylfolate augmentation in depressive disorders. Pharmacopsychiatry. 2022;55(3):139-147.

16. Papakostas GI, Shelton RC, Zajecka JM, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012;169(12):1267-1274.

17. Menon V, Kar SK, Suthar N, Nebhinani N. Vitamin D and depression: a critical appraisal of the evidence and future directions. Indian J Psychol Med. 2020;42(1):11-21.

18. El Dib R, Periyasamy AG, de Barros JL, et al. Probiotics for the treatment of depression and anxiety: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2021;45:75-90.

19. Miyaoka T, Kanayama M, Wake R, et al. Clostridium butyricum MIYAIRI 588 as adjunctive therapy for treatment-resistant major depressive disorder: a prospective open-label trial. Clin Neuropharmacol. 2018;41(5):151-155.

20. Johnson D, Letchumanan V, Thum CC, et al. A microbial-based approach to mental health: the potential of probiotics in the treatment of depression. Nutrients. 2023;15(6):1382.

21. Yolland CO, Hanratty D, Neill E, et al. Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia. Aust N Z J Psychiatry. 2020;54(5):453-466.

22. Herxheimer A, Petrie KJ. Melatonin for preventing and treating jet lag. Cochrane Database Syst Rev. 2001;2002(1):CD001520.